NCT03601117

Accelerated Intermittent Theta Burst Stimulation for Depressive Symptoms

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates an accelerated schedule of theta-burst stimulation for depressive symptoms in psychiatric inpatients. A small pilot study (n=22) will be carried out to demonstrate feasibility, using the FDA-approved stimulation site for depression treatment (L-DLPFC). Participants will be offered stimulation at the anterior cingulate cortex (ACC).

Detailed description

This study intends to investigate whether modifying stimulation parameters enables typical 6-8 week long rTMS protocols to be compressed to only five days. The influence of this accelerated protocol on the length of patient stay in the hospital will be investigated.

Conditions

• Depression and Suicide

Interventions

Type	Name	Description
DEVICE	Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation	Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Brainsway TMS system.
DEVICE	Anterior Cingulate Cortex Accelerated Theta Burst Stimulation	Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC). Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Brainsway TMS system.

Timeline

• Start date: 2018-07-01
• Primary completion: 2020-06-01
• Completion: 2020-06-01
• First posted: 2018-07-26
• Last updated: 2022-05-18
• Results posted: 2021-08-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study